VERU Earnings

VERU reported its earnings on 2026-02-11, showcasing a revenue of 0.00 against an estimate of , resulting in a 0% surprise. The EPS was -0.26, surpassing the expected -0.47 by 44.68%. The stock experienced a -0.43% price change on the earnings day and a 1.73% change over the next five days, reflecting market reactions to the results.

Following VERU's earnings announcement on 2026-02-11, the stock price moved by -0.43% on the day of the release. Over the subsequent five days, it saw a 1.73% change. Historically, VERU's stock price tends to shift by an average of 5.27% in the 10 days leading up to earnings and 6.33% in the 10 days following, providing insight into potential market.

For 2024/Q1, analysts estimate VERU's annual revenue to reach 6.50M, while the EPS is projected at -0.37. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between VERU's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, VERU's stock price typically moves by 5.27% in the 10 days before its earnings and 6.33% in the 10 days after. For the upcoming 2024/Q1 earnings, analysts expect an EPS of -0.37 and revenue of 6.50M.

The earnings call presents a mixed picture. While there are positive developments in clinical trials and financial improvements, significant risks and challenges remain. The regulatory hurdles for enobosarm, bone density concerns, and intense market competition could weigh on investor sentiment. The Q&A session did not reveal any new risks, but the lack of profitability and the need for clear market advantages are concerns. The financial position shows improved cash reserves, but sustainability is uncertain. These factors balance each other out, leading to a neutral sentiment rating.